[HTML][HTML] Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous …

CA Parkinson, D Gale, AM Piskorz, H Biggs… - PLoS …, 2016 - journals.plos.org
Background Circulating tumour DNA (ctDNA) carrying tumour-specific sequence alterations
may provide a minimally invasive means to dynamically assess tumour burden and …

[HTML][HTML] Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer

FC Martins, DL Couturier, I De Santiago… - Nature …, 2022 - nature.com
Chromosomal instability is a major challenge to patient stratification and targeted drug
development for high-grade serous ovarian carcinoma (HGSOC). Here we show that …

Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer

H Song, EM Dicks, J Tyrer, M Intermaggio… - Journal of medical …, 2021 - jmg.bmj.com
Purpose The known epithelial ovarian cancer (EOC) susceptibility genes account for less
than 50% of the heritable risk of ovarian cancer suggesting that other susceptibility genes …

Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models

CM Sauer, K Heider, J Belic, SE Boyle… - EMBO Molecular …, 2022 - embopress.org
Whole‐genome sequencing (WGS) of circulating tumour DNA (ctDNA) is now a clinically
important biomarker for predicting therapy response, disease burden and disease …

[HTML][HTML] Molecular landscape and functional characterization of centrosome amplification in ovarian cancer

CM Sauer, JA Hall, DL Couturier, T Bradley… - Nature …, 2023 - nature.com
High-grade serous ovarian carcinoma (HGSOC) is characterised by poor outcome and
extreme chromosome instability (CIN). Therapies targeting centrosome amplification (CA), a …

Epirubicin, cisplatin, and capecitabine for primary platinum-resistant or platinum-refractory epithelial ovarian cancer: results of a retrospective, single-institution study

K Sayal, I Gounaris, B Basu, S Freeman… - International Journal of …, 2015 - ijgc.bmj.com
Objective Primary platinum-resistant epithelial ovarian cancer (EOC) is an area of unmet
medical need. There is limited evidence from small studies that platinum-based …

Stimulus probability as a determinant of discrete choice reaction time.

HL Hawkins, K Hosking - Journal of Experimental Psychology, 1969 - psycnet.apa.org
Tested the hypothesis that stimulus probability is a critical determinant of choice RT only
when stimulus alternatives are represented within Ss positive set, ie, the stored alternatives …

Scanning strategies and differential sensitivity in a visual signal detection task: Intrasubject reliability

DE Clement, KE Hosking - Psychonomic Science, 1971 - Springer
Four Ss (two of each sex) were run on 960 trials of a 16-alternative forced-choice visual
signal detection task. Analysis of variance of d'values indicated the usual practice effects, as …

Predicting response to cytotoxic chemotherapy

JS Thompson, L Madrid, B Hernando, CM Sauer… - bioRxiv, 2023 - biorxiv.org
Cytotoxic chemotherapies have been a crucial part of cancer treatment for over 40 years.
While their primary target is cancer cells, they can also harm normal cells, resulting in dose …

Circulating tumour DNA carrying patient-specific mutations in TP53 as an early response biomarker in relapsed high grade serous ovarian cancer.

CA Parkinson, D Gale, A Piskorz, C Hodgkin, H Biggs… - 2016 - ascopubs.org
e23040 Background: Novel biomarkers are required to accurately assess tumour burden
and response in cancer. In patients with relapsed high-grade serous ovarian carcinoma …